Skip to content

Author

Jana Y. Waldmann

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Optimal drug, dose and duration of antipsychotic therapy following amphetamine and cannabis-induced psychosis: A systematic review.

BACKGROUND Amphetamine- and cannabis-induced psychoses are common clinical presentations that are difficult to differentiate from primary psychotic disorders. However, there are limited guidelines around the appropriate use of antipsychotic medications to treat these disorders. This review examined the literature consi...

E. Hall, Nisitha Ratnayake, Jana Y. Waldmann et al. · 0 citations
Review Aug 2026

Varenicline for the management of cannabis use disorder: A systematic review.

INTRODUCTION Cannabis use disorder (CUD) is one of the highest prevalence mental health conditions globally. Psychosocial treatments for CUD have modest efficacy. There are currently no approved adjunctive pharmacological approaches for CUD. Varenicline, a nicotinic receptor partial agonist approved for use in smoking...

Courtney Craig, Jana Y. Waldmann, Mark R. C. Daglish et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.